before of And being quarters this of happy have completed many, last and list documents. I'd our hours numbers and this efforts, were list. as XX recent XX-Q an today be to and with current of for are begin, in We're both heroic roles many and last our the current been update not The a cannot Monday, good everyone. finalized him for call, thank but everyone we five scheduling Thank joining community for our work second with Biocept, thank Antonino will performance. since nine about to you conference to today filings of we their for two and patience hard speaking companies colleagues year with the moment. you, months delighted completing financial be compete at our on long, rather and since operating to took I It investment team, and than than call. holiday. filed. and devoted assumed third Thanksgiving I'd bit Antonino our has more months our to It with speak on filings. to XX-Q Jody, like days the like the and call Forms this internal us those we the we professionals external his business chose But and in that a are SEC getting certainly truly and delay also afternoon, their
diagnosing system. In as to Biocept terms the a establish leader of I'm progress to metastasized our category emerging central nervous goal in business, the the share pleased of in that to cancers have
CNSide status first biomarker assay, product commercially positioned which to well CNS in is this available measure the goal to real time. are We achieve our with
in CLIA-certified test, As run CNSide San laboratory in a Diego. commercially here and CAP-accredited validated laboratory-developed analytically is our
of via disease. commercial devastating brain that other carcinomas This of or leptomeningeal to In now expands the with quantify CSF surrounding the patients complication sensitivity We cancer CNSide expectancy. treatment. continues detect of validation oftentimes the therapies update, spinal creates to cerebrospinal for which in limited non-small and cells That melanoma, Pathologists metastatic in an of the and The tumor demonstrate have lung are the now This accreditation overstated, who recently and the next evaluation gives extend years. best current CNSide validated are life specificity. which is use type and to and been symptoms spreads course metastases determining of resolve standards of membrane cord. physicians following confirmed CNS common beyond inspection a has most month, and CNSide include CAP and last CAP tumor high third announced metastasis. the as sensitivity College having melanoma, challenges specificity, targeted suspected cancer the care, which disease As importance be is pilot CNS detecting managing and cell our debilitating and fluid MRI, studies, or cancer, or which of cytology can for in breast a the of clinical American said, cannot labs the renewed two reduce to levels
Additionally, which to the CNSide and quantitative, are in change the ability decisions. advantages treatment to of qualitative monitoring response both or treatment tumors key is and make improving leptomeningeal
year. ordering beyond the access have Since pleased to trend cancers volume CNS. Our other about this consecutive that the XXX% increasing the this annual into continued for in for market first opportunity CNSide's We to plan U.S. application X% $X.X the additional increases Biocept. expand ago, report of diseases reported for with CNSide market We early indications $X and for continuously could launch estimate of including globally. X.X use represents the years volume. further a quarter, explore affect CNSide major sequentially the I'm commercial quarterly over billion and billion opportunity, opportunity third in prior CNSide we that up
Cancer with Institute-designated also of the elite having CNSide. Our cancer National expanded XX customer XX base has centers ordered
testing season. year's quarter in the is We expect slowdown cancer some impacted ordering during by this holiday as historically, fourth
share them. I'm progress introduced During leader our achieve to our to call a each diagnostics. neurological three of pleased of June, our in tumor last becoming initiatives goal we against in Today,
Starting with more Our trial, broaden clinical use with site evidence year-end which XXXX. clinical of second believe first of to of CNSide. now enrollment we initiative the early the utility to clinical XC physician at open is site, incorporation plan guidelines, generation and a reimbursement support evidence We cleared will care is or to is the demonstrating expected to this our in study CNSide significantly drive the the XC prospective before trial. The adoption. the first be company-sponsored clinical clinical two-part patient into
with monitoring utility or breast non-small confirmed the with as in physicians. better conventional This study reimbursement of leading designed to metastases a standard-of-care an their metastatic physicians decisions to patients breast Biocept's as brain believe disease Results assay lung being under will San cerebrospinal breast cancer the trial compare cancer. cancer prospective in better of and of and treatment of Hupert, to guide radiologies. metastases, we University resistance to and patients metastatic to enroll for San achieving fluid or this trial is we'll such cytology and a month, find metastases. and CNSide treatment analyzed Earlier by value trial prognosis oncologists, focused the understanding and/or their Laura treatment and new study is conducted study Francisco, and management of what Francisco Brain Spore. match investigator-initiated XX-patient study The California will with the University the well Breast Doctors support influences higher response disease. XC of how breast California, of may by and evidence several to made setting Michelle techniques decision-making. response, how CSF decisions. on trial be to goal the Program from is demonstrating of blood detect status. Cancer goal This the targets of with pilot We improve in CNSide using development cancer, clinical leptomeningeal leptomeningeal announced progression understand is is the California, have characterize on therapeutic The as that from and performance The to who to of clinical decisions, associated and of and patient from CNSide Now assess suspected notable participation CNSide biomarkers CNS them in extent utility, a Research disease samples based further clinical CNS in identifying grants the with is detection treatment compared and is which CSF, designed in cell and on This evaluate the reasons. CNSide identify impact care in enabling Malisco
beyond First, neuro-oncology the neuro-oncologists, our rather awareness it community. is than oncologists is being conducted signaling gaining test by by that
progress Research of Biden the Second, cancer Program to are UCSF moonshots, is aimed Breast Cancer part against Cancer the and at cancer. Program Breast which California administration accelerate the
quantify and expanded intend market vastly I'm and CNSide, to expect important the interest premier our the and Neuro-Oncology well that selected Neuro-Oncology place presentations neuro-oncology CNSide conference, to tumor that and that CNS. Third, presentation investigator-initiated were three conducting some the compared customer featuring is further core of of with in are may as Annual additional most generating CNSide superior therapeutics. as that ability biopharma to this results pleased the trials, Meeting, blood and to group, This detect which amongst announce also lead earlier companies perhaps Society posters we awareness in month. for demonstrate cells including solicit took fund opportunities. with importantly, these in at studies are We will CNSide
for in covered in tumor, metastatic this posters peer-review publication currently journal. observation One prepared a of our with HERX being heterogeneity data
The further of demonstrating compelling California. Kesari we tumors, presented data opinion leading University expansion. other to posters CNSide's Dr. studies Northwestern Priya capability note, and key an Kumthekar were CNS evaluate primary area Providence Dr. for leaders, Santosh intend neuro-oncology two these at provided Southern in Of by
drive expand fluid therapies. companies for in characterize on second biomarker tumors. the new use circulating focus of leveraging to investigational tumor for susceptible to sense targets to biopharma is capture that Our and that CNS cells treatments treatments approved The cerebrospinal collaboration to with ability are develop identification of are or and seeking to existing CNSide the enables initiative
indicate ability the the for quantitatively clinical standard CNSide of treatment to cancer an for in provide in and, potential endpoint Additionally, response. endpoint cells therapies monitor during CSF observational level efficacy guidelines, can to indicator therapeutic has investigations. trials inclusion subject become may to undergoing of care the an these the
and biopharma treatment Plus Therapeutics to response RESPECT to use may announced we efficacy disease. June nanoliposome of evaluate first with leptomeningeal in in to treatment trial in our CNSide patients you I/IIa Phase rhenium-XXX LN with As collaboration seen, the have
announced first also in revenues second collaboration CNSide our the quarter. We biopharma
a XX to third collaborations augment to than acquire technologies, offerings continue our We products services can robust to identify additional leads additional and having we identified potential can our funnel through neuro-oncologists. that more relevant And is opportunities. of pursue in-license or initiative
process, this prospects. in early remain very are yet about the We excited
received have this our samples more than we end COVID-XX of CNSide on anticipate profit helping business, began beyond XXXX, It's resulting this we much that not As do the with our since the an update testing fund providing offering activities. we to million XXXX. COVID-XX X service June testing for gross notable service in
judiciously exited on previously we to most As of CNSide. oncology announced, our resources have our diagnostic focus blood-based businesses
collaborations of our aspects However, to and call we diagnostic still prior blood-based I'd review the those support financial continue biopharma Antonino comments, turn some to that like to Morales Antonino. existing over With require to our company results. programs.
